var data={"title":"Tegaserod (United States: Available via FDA emergency access protocol only): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Tegaserod (United States: Available via FDA emergency access protocol only): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7012?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224906\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Zelnorm</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224927\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Serotonin 5-HT<sub>4</sub> Receptor Agonist</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224909\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>IBS with constipation: </b>Females &lt;55 years of age: Oral: 6 mg twice daily, before meals, for 4-6 weeks; may consider continuing treatment for an additional 4-6 weeks in patients who respond initially </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Chronic idiopathic constipation:</b> Females &lt;55 years of age: Oral: 6 mg twice daily, before meals; the need for continued therapy should be reassessed periodically </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224910\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Use in elderly women (&ge;55 years of age) is contraindicated.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224911\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">C<sub>max</sub> and AUC of the inactive metabolite are increased with renal impairment. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Mild-to-moderate impairment: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Severe impairment: Use is contraindicated.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224912\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">C<sub>max</sub> and AUC of tegaserod are increased with hepatic impairment. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Mild impairment: No dosage adjustment necessary. Use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Moderate-to-severe impairment: Use is contraindicated.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224884\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zelnorm: 2 mg, 6 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224873\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28797859\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Zelnorm is only available in the US via an emergency investigational new drug (IND) process. Physicians with patients who may qualify can contact the FDA&rsquo;s Division of Drug Information at druginfo@fda.hhs.gov or 301-796-3400.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11234337\" class=\"block accres drugH1Div\"><span class=\"drugH1\">Prescribing and Access Restrictions</span>\n    <p style=\"text-indent:0em;display:inline\">Available in U.S. under an emergency investigational new drug (IND) process. Emergency situations are defined as immediately life-threatening or requiring hospitalization. Physicians with patients who may qualify can contact the FDA&rsquo;s Division of Drug Information at  druginfo@fda.hhs.gov or 301-796-3400. The FDA may either deny the request or authorize shipment of Zelnorm&reg; by Novartis. Additional information can be found at <a target=\"_blank\" href=\"http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm103223.htm&amp;token=UVXgXvDhi50fnIatJw1GVV8CoioIcBwhVHvK28Rc+luGcqI2QXitqmscyy5fFbTMUQeKwUJQaDkWCcXvymCAGP+jop+VlWDZ7cJffpOUZO5dgOL9msui6nKEYkCETdm/&amp;TOPIC_ID=10200\" target=\"_blank\">http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm103223.htm</a>.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224886\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer 30 minutes before meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224885\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Emergency treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) in women (&lt;55 years of age) in which no alternative therapy exists</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224878\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal pain (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness (4%), migraine (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (9%; severe: &lt;1%; severe diarrhea was complicated by hypovolemia, hypotension, syncope), nausea (8%), flatulence (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Back pain (5%), arthropathy (2%), leg pain (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Albuminuria, alopecia, angina pectoris, appendicitis, asthma, attempted suicide, breast carcinoma, bundle branch block, cardiac arrhythmia, cerebrovascular accident, cholecystitis (with or without increased serum transaminases), choledocholithiasis, depression, diaphoresis, emotional lability, eructation, facial edema, fecal incontinence, flushing, hepatitis, hypermenorrhea, hypersensitivity reaction, hypotension, increased appetite, increased creatine phosphokinase, increased serum ALT, increased serum AST, increased serum bilirubin, intestinal obstruction, irritable bowel syndrome, ischemic colitis, lack of concentration, local tissue necrosis (gangrenous bowel), mesenteric ischemia, muscle cramps, myocardial infarction, ovarian cyst, pain, polyuria, pruritus, rectal hemorrhage, renal pain, sleep disorder, spasm of sphincter of Oddi (suspected), supraventricular tachycardia, syncope, tenesmus, unstable angina pectoris, vertigo</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224889\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Per product labeling: Hypersensitivity to tegaserod or any component of the formulation; severe renal impairment; moderate or severe hepatic impairment; history of bowel obstruction, symptomatic gallbladder disease, suspected sphincter of Oddi dysfunction, or abdominal adhesions</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Exclusion criteria under the emergency-IND process: Unstable angina, history of MI or stroke, hypertension, hyperlipidemia, diabetes, age &ge;55 years, smoking, obesity, depression, anxiety, or suicidal ideation. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224876\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse reactions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cardiovascular effects: Serious cardiovascular events (eg, MI, stroke, unstable angina) may occur; patients should seek emergency care following any sign and symptom suggestive of a serious cardiac event.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Diarrhea: May occur after the start of treatment, most cases reported as a single episode within the first week of therapy, and may resolve with continued dosing. However, serious consequences of diarrhea (hypovolemia, syncope) have been reported; patients should be warned to contact healthcare provider immediately if they develop severe diarrhea, or diarrhea with severe cramping, abdominal pain, or dizziness.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Intestinal ischemic events: Use has been associated with rare intestinal ischemic events; discontinue immediately with new or sudden worsening abdominal pain or rectal bleeding.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cardiovascular disease: Use will not be permitted in patients with unstable angina, a history of MI or stroke, hyperlipidemia, cigarette smoking, hypertension, or obesity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Depression: Use will not be permitted in patients with depression or anxiety, or with any signs of suicidal ideation or behavior.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Diabetes: Use will not be permitted in patients with diabetes.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Use with caution in patients with mild hepatic impairment; not recommended with moderate or severe impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elderly women: Contraindicated in women &ge;55 years of age.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Males: Safety and efficacy have not been established in males.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Risk vs benefit: Potential benefits should be weighed against potential risks in qualifying patients eligible for emergency-IND use.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300106\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6223182\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10200&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224903\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Bioavailability is decreased by 40% to 65% and C<sub>max</sub> is decreased by 20% to 40% when taken with food. T<sub>max</sub> is prolonged from 1 hour up to 2 hours when taken following a meal, but decreased to 0.7 hours when taken 30 minutes before a meal. Management: Take on an empty stomach 30 minutes before meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224881\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224892\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed in animal reproduction studies. Pregnant women were excluded from clinical trials and outcome information following inadvertent pregnancy exposure is limited (Appel-Dingemanse, 2002).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F17916879\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if tegaserod is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224893\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Take on an empty stomach, 30 minutes before meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224875\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Tegaserod is a partial neuronal 5-HT<sub>4</sub> receptor agonist. Its action at the receptor site leads to stimulation of the peristaltic reflex and intestinal secretion, and moderation of visceral sensitivity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224888\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: 368 &plusmn; 223 L </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 98% primarily to &alpha;<sub>1</sub>-acid glycoprotein </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: GI: Hydrolysis in the stomach; Hepatic: Oxidation, conjugation, and glucuronidation; metabolite (negligible activity); significant first-pass effect </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Fasting: 10% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: IV: 11 &plusmn; 5 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: 1 hour </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Feces (~66% as unchanged drug); urine (~33% as metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224894\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Colonaid (CL, PY);</li>\n      <li>Coloserod (UY);</li>\n      <li>Gasprid (CO);</li>\n      <li>Tegibs (IN);</li>\n      <li>Zelmac (AE, AR, AU, BH, BR, CH, CN, CZ, EC, EG, HK, ID, IL, KR, MX, MY, NZ, PE, PK, QA, SA, SG, TH, TW, VE, VN);</li>\n      <li>Zelnorm (PH);</li>\n      <li>Zerada (CR, DO, GT, HN, NI, PA, SV)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Appel-Dingemanse S, &quot;Clinical Pharmacokinetics of Tegaserod, a Serotonin 5-HT(4) Receptor Partial Agonist With Promotile Activity,&quot; <i>Clin Pharmacokinet</i>, 2002, 41(13):1021-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tegaserod-united-states-available-via-fda-emergency-access-protocol-only-drug-information/abstract-text/12403641/pubmed\" target=\"_blank\" id=\"12403641\">12403641</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zelnorm (tegaserod maleate) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; July 2006.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10200 Version 62.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F224906\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F224927\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F224909\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F224910\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F224911\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F224912\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F224884\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F224873\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F28797859\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Prescribing and Access Restrictions\" href=\"#F11234337\" class=\"outlineLink\">Prescribing and Access Restrictions</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F224886\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F224885\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F224878\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F224889\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F224876\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300106\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6223182\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F224903\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F224881\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F224892\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F17916879\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F224893\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F224875\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F224888\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F224894\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10200|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div>","javascript":null}